Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

Marie Skłodowska-Curie Action · Running

NINFA-AD Neuropsychiatric Impairments and Neurotransmitter-related Functional Alterations in Alzheimer’s Disease

Coordinator
Universita Degli Studi Di Parma, Italy
Runs
1 June 2025 to 31 May 2027
Status
Running
EU funding
€173k
Total cost
—
Partners
2 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101149449

What the project is doing

In the project's own words, from its summary on CORDIS.

Depressed mood, agitation, false beliefs, lack of motivation and other alterations in behaviour, usually named with the umbrella term of neuropsychiatric symptoms (NPS), are commonly observed in people with Alzheimers disease (AD). NPS are highly prevalent in people with AD (35-85%) and increase the risk of dementia by up to 10 times. The onset of NPS may even precede that of cognitive deficits and predict subsequent cognitive decline.

Although not all patients experience NPS and some experience only very mild symptoms, clarifying AD aetiology is of primary importance to improve early diagnosis, provide better care and mitigate the economic burden of dementia. The neural changes associated with NPS in AD are still unclear and, consequently, wide consensus on the best treatment strategies is lacking. Since the earliest accumulation of AD pathology is observed in the nuclei involved in the production of neurotransmitters, the NINFA-AD project aims to investigate whether alterations in brain functioning influenced by abnormalities in different neurotransmitter pathways may be associated with NPS in people either with or at risk for AD.

This aim will be pursued by applying an innovative interdisciplinary approach combining functional magnetic resonance with positron emission tomography imaging, fluid AD biomarkers and cognitive data. The NINFA-AD project will provide novel hypothesis-based insights on the cause of these symptoms that will lead to more efficient treatments and improvements in patients' prognosis. Moreover, the findings could be exploited to develop more informative biomarkers to be used in trials to test the mechanisms of action and effectiveness of novel interventions targeting behavioural problems in AD.

Topics

Who is involved

OrganisationCityCountryRole
Universita Degli Studi Di ParmaParmaItalyCoordinator
Azienda Ospedaliero-Universitaria Di ParmaParmaItalyAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI